株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

転移性ぶどう膜黒色腫:パイプライン製品の分析

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 305183
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=116.15円で換算しております。
Back to Top
転移性ぶどう膜黒色腫:パイプライン製品の分析 Metastatic Uveal Melanoma - Pipeline Review, H2 2016
出版日: 2016年12月30日 ページ情報: 英文 56 Pages
概要

転移性ぶどう膜黒色腫とは、眼球(ぶどう膜)から人体の他の部位へと転移していくがんを指します。肝臓への転移が最も多く、また肺・骨・皮膚直下(皮下)への転移も多く見られます。主な症状には黄疸や皮膚の痒み・発疹、肝臓内部の酵素の異常増加、腹痛、食欲不振、吐き気・嘔吐などが挙げられます。主な治療法には、外科手術や化学療法、放射線治療などがあります。

当レポートでは、世界各国での転移性ぶどう膜黒色腫治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

転移性ぶどう膜黒色腫の概要

治療薬の開発

  • 転移性ぶどう膜黒色腫向けパイプライン製品:概要
  • 転移性ぶどう膜黒色腫向けパイプライン製品:比較分析

各企業で開発中の転移性ぶどう膜黒色腫治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品

転移性ぶどう膜黒色腫治療薬:開発中の製品の一覧(企業別)

転移性ぶどう膜黒色腫治療薬の開発に従事している企業

  • AstraZeneca PLC
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.

転移性ぶどう膜黒色腫:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 硫酸セルメチニブ
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • リンゴ酸スニチニブ
  • 硫酸ビンクリスチン・リポソーム
  • LY-2801653
  • 酢酸ソトラスタウリン
  • MEK-162

転移性ぶどう膜黒色腫治療薬:パイプライン製品の最新動向

転移性ぶどう膜黒色腫治療薬:開発が休止状態の製品

転移性ぶどう膜黒色腫の関連製品の開発マイルストーン

  • 注目すべき最新動向・プレスリリース(全2件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8909IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides an overview of the Metastatic Uveal Melanoma (Oncology) pipeline landscape.

Metastatic uveal melanoma is a cancer that has spread from the eye (uveal) to other parts of the body. The most common site of metastasis for uveal melanoma is the liver. Other common sites of metastasis include the lung, bones and just beneath the skin (subcutaneous). Symptoms include jaundice, itchy skin or rash, abnormally high enzymes in the liver, abdominal pain, appetite loss, nausea, and vomiting. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and IND/CTA Filed stages are 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Metastatic Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Metastatic Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metastatic Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metastatic Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Uveal Melanoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metastatic Uveal Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Uveal Melanoma Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Uveal Melanoma - Overview
    • Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis
  • Metastatic Uveal Melanoma - Therapeutics under Development by Companies
  • Metastatic Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Uveal Melanoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Uveal Melanoma - Products under Development by Companies
  • Metastatic Uveal Melanoma - Products under Investigation by Universities/Institutes
  • Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development
    • Bellicum Pharmaceuticals Inc
    • Celldex Therapeutics Inc
    • Eli Lilly and Company
    • Novartis AG
    • Spectrum Pharmaceuticals Inc
  • Metastatic Uveal Melanoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPX-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emibetuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glembatumumab vedotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KCN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LXS-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • merestinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sotrastaurin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vincristine sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metastatic Uveal Melanoma - Dormant Projects
  • Metastatic Uveal Melanoma - Discontinued Products
  • Metastatic Uveal Melanoma - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016
      • Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Uveal Melanoma, H2 2016
  • Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Uveal Melanoma - Dormant Projects, H2 2016
  • Metastatic Uveal Melanoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Metastatic Uveal Melanoma, H2 2016
  • Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top